NCT01112527View on ClinicalTrials.gov

PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
GlioblastomaGBMGlioblastoma Multiforme
Interventions
DRUG

PF-00299804

Taken orally once a day

Trial Locations (4)

44195

Cleveland Clinic, Cleveland

48202

Henry Ford Hospital, Detroit

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Henry Ford Hospital

OTHER

collaborator

Pfizer

INDUSTRY

lead

Massachusetts General Hospital

OTHER